Supplementation of high-fat or db/db mice with either TGR5 or FXR agonists inhibits lipogenesis, induces energy expenditure and reduces hepatic and renal inflammation to reduce the development of NAFLD and DKD 124. Here, GPBAR1 is linked to metabolic dysfunction-associated steatotic liver disease.